





























Journal of the American College of Cardiology Vol. 44, No. 11, 2004
© 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00
PIEWPOINT
roposal for Contemporary Screening Strategies
n Families With Hypertrophic Cardiomyopathy
arry J. Maron, MD, FACC,* J. G. Seidman, PHD,*† Christine E. Seidman, MD*†
inneapolis, Minnesota; and Boston, Massachusetts
Screening families with hypertrophic cardiomyopathy (HCM) presents a common clinical
problem to practicing cardiologists, internists, and pediatricians. The traditional recom-
mended strategy for screening relatives in most HCM families calls for such evaluations with
echocardiography (and electrocardiogram [ECG]) on a 12- to 18-month basis, usually
beginning at about age 12 years. If such tests show no evidence of left ventricular hypertrophy,
i.e., without one or more segments of abnormally increased wall thickness by the time full
growth and maturation is achieved (at the age of about 18 to 21 years), it has been customary
practice to conclude that HCM is probably absent and reassure family members accordingly
that further echocardiographic testing is unnecessary. However, novel developments in the
definition of the genetic causes of HCM have defined both substantial molecular diversity and
heterogeneity of the disease expression including (in some relatives) incomplete phenotypic
penetrance and delayed, late-onset left ventricular hypertrophy well into adulthood. These
observations have unavoidably reshaped the customary practice of genetic counseling and
established a new proposed paradigm for clinical family screening of HCM families.
Therefore, in the absence of genetic testing, strong consideration should be given to
extending diagnostic serial echocardiography past adolescence and into mid-life for those
family members with a normal echocardiogram and ECG. Of note, recent developments in
laboratory DNA-based diagnosis for HCM could potentially avoid the necessity for serial
echocardiography in many such relatives. (J Am Coll Cardiol 2004;44:2125–32) © 2004 by


























mypertrophic cardiomyopathy (HCM) is a familial cardiac
isease caused by a variety of mutant genes encoding protein
omponents of the cardiac sarcomere, transmitted to each
onsecutive generation as an autosomal dominant trait with
ariable penetrance and heterogeneous clinical expression
1–36). Hypertrophic cardiomyopathy is the most common
f the genetic cardiovascular diseases, occurring in about 1
n 500 of the general population (based on echocardio-
raphic recognition of the phenotype) (37–41). This esti-
ate suggests that as many as 500,000 people in the U.S.
ay be affected by this condition (42). However, the
elatively low prevalence of HCM in clinical cardiologic
ractice (43) suggests that many affected (and largely
symptomatic) relatives remain undiagnosed and unaware of
heir underlying disease or genetic status, possibly due in
ome instances to the variable and incomplete age-
ependent penetrance now known to be associated with
ertain disease-causing mutant genes.
The Mendelian autosomal dominant inheritance pattern
f HCM has been established during the more than 40 years
ince the earliest clinical descriptions of the disease in the
ate 1950s and early 1960s (44,45). However, not until the
pplication of molecular biology to HCM over the past 15
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ccepted August 27, 2004.ears has the genetic complexity and heterogeneity of HCM
een fully appreciated (1–36,46–49). Advances in our
nderstanding of HCM, as a consequence of the power
mplicit in mutational analysis, have occurred in two prin-
ipal areas. The first of these is the development of genetic
arkers for stratification of sudden death risk and other
dverse consequences of HCM (1–36,47). However, the
xtent to which precise knowledge of particular disease-
ausing mutations will prove useful in predicting prognosis
nd designing management strategies for individual HCM
atients is incompletely resolved (48,49) and has not been
ncluded in the present discussion.
Second, the capability of achieving an unequivocal diag-
osis of HCM with deoxyribonucleic acid (DNA)-based
aboratory methods is irrefutable and has led to enhanced
ecognition of the HCM disease state, and consequently to
ore complete definition of its broad clinical spectrum, as
ell as providing practical insights into appropriate genetic
ounseling (1–36,46–49). Indeed, there is substantial justi-
cation for pursuing and encouraging the clinical and
enetic screening of families for HCM in order to recognize
ffected individuals who would otherwise be unaware of
heir disease. This includes the opportunity to identify
atients who may be at high risk for sudden death and,
herefore, eligible for preventive strategies (42,50). Al-
hough such considerations importantly affect ambulatory
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Family Screening in HCM December 7, 2004:2125–32any published basic science and clinical reports containing
enetic data relevant to HCM may be difficult to decipher
nd formulate, given the vast and complex (and sometimes
eemingly contradictory) literature available in this disease.
herefore, we regard this as an opportune and timely
uncture to revisit the issue of family screening and its
anagement implications for HCM against the landscape
f contemporary developments in molecular biology.
CM GENOTYPE
olecular studies with clinical genotype-phenotype corre-
ations, conducted intensively over more than a decade, have
rovided important insights into the genetics of HCM, as
ell as access to definitive laboratory-based diagnosis by
irtue of detecting pathologic mutations, even in the ab-
ence of obvious clinical evidence of the disease (1–36,
6–49,51–56). This substantial investigative effort has
emonstrated convincingly that HCM is caused by muta-
ions in any one of 10 genes, each encoding a protein
omponent of the cardiac sarcomere, i.e., either of the thick
r thin filaments with contractile, structural, or regulatory
unctions. Therefore, from the perspective of these basic
bservations, it is presently possible to regard most of the
iverse clinical spectrum of HCM as both a unified disease
ntity and a fundamental and primary disorder of the
arcomere (7). Two of the HCM-causing mutant genes,
eta-myosin heavy chain (the first identified) and myosin-
inding protein C, appear to predominate in frequency. The
ther eight genes appear to account for far fewer cases of
CM and include troponin T and I, regulatory and
ssential myosin light chains, titin, alpha-tropomyosin,
lpha-actin, and alpha-myosin heavy chain. This genetic
iversity is compounded by the considerable intragenic
eterogeneity, with more than 200 mutations now identi-
ed. These are most commonly missense mutations with a
ingle amino acid residue substituted for another, but also
nclude insertions, deletions, and splice (split site) mutations
ncoding truncated sarcomeric proteins. The characteristic
orphologic diversity of the HCM phenotype is largely
ttributable to the disease-causing mutations, but also prob-
bly to the influence of modifier genes and environmental
actors on phenotypic expression.
In addition, non-sarcomeric protein missense mutations
ave been recently reported to be responsible for primary
ardiac disease with the clinical presentation of HCM. The
rst of these involves the gene encoding the gamma-2-
Abbreviations and Acronyms
DNA  deoxyribonucleic acid
ECG  electrocardiogram/electrocardiographic
HCM  hypertrophic cardiomyopathy
LV  left ventricle/ventricular
PRKAG2  AMP-activated protein kinaseegulatory subunit of the AMP-activated protein kinase oPRKAG2) which may occasionally cause familial, relatively
ild left ventricular (LV) hypertrophy associated with
entricular pre-excitation (54 –56). Patients harboring
RKAG2 mutations are distinguished from those with
ypical sarcomere protein gene mutations by absence of
istopathologic features characteristic of HCM (i.e., myo-
yte disarray), progressive conduction system disease with
eart block, and a distinct metabolic-based cause for the
ypertrophy with glycogen accumulation evident in myo-
ytes (54).
Most recently, a non-sarcomeric mutant gene has been
dentified involving the lysosome-associated membrane pro-
eins 2 alpha-galactosidase or acid alpha-1, 4-glucosidase,
nd causing clinically diagnosed HCM (52). This results in
glycogen storage disease (Danon disease) with clinical
anifestations largely limited to the heart, usually associ-
ted with ventricular pre-excitation and massive degrees of
V hypertrophy (52). Undoubtedly, many other mutations
ausing HCM in sarcomere (as well as non-sarcomere)
elated genes remain to be identified.
Although laboratory DNA analysis for mutant genes is
he most definitive method for establishing the diagnosis of
CM, important obstacles remain for translating such
esearch-based genetic technology into practical clinical
trategies on a widespread or routine basis (1,2,6,10,48,49).
hese factors include the aforementioned genetic heteroge-
eity of HCM, as well as the methodologic difficulties
ssociated with identifying a single disease-causing muta-
ion among a total of at least 12 possible HCM genes, given
he complex, time-consuming and expensive laboratory
echniques required. However, when an HCM mutation is
uccessfully identified in a proband, accurate definition of
enetic status can be achieved in all family members much
ore efficiently and inexpensively. Academic diagnostic
olecular laboratories have recently begun to address these
hallenges and opportunities by offering DNA testing for a
ubset of HCM disease genes.
CM PHENOTYPE
iagnostic echocardiographic studies in HCM are triggered
ost commonly by new cardiac symptoms, a systolic heart
urmur, an abnormal electrocardiogram (ECG), or fre-
uently by recognition of the disease in family members
2,5,41,43–45,57). Indeed, in the vast majority of patients,
ecognition of HCM continues to be customarily based on
wo-dimensional echocardiographic identification of the
iverse disease phenotype, which includes a myriad of
atterns, extent, and magnitude of LV wall thickening
2,58). In addition, contemporary magnetic resonance im-
ging (which provides high-resolution tomographic images
f the entire LV chamber) may be a useful diagnostic
odality in selected patients or family members (59,60).
his is particularly true when echocardiographic studies are
echnically suboptimal or when segmental hypertrophy or
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December 7, 2004:2125–32 Family Screening in HCMithin the LV chamber such as the anterolateral free wall or
pex.
It has been a historical dictum in HCM that, in the
bsence of another cardiac disease capable of producing
he magnitude of LV hypertrophy evident, an abnormally
ncreased LV wall thickness (usually 15 mm in adults)
ssociated with a non-dilated chamber represents the
linical marker and evidence of an underlying mutant
CM gene (2,5,10,37,58,61). Borderline LV wall thick-
esses of 13 or 14 mm in an adult patient are regarded as
ossible evidence of HCM, but often elicit a differential
iagnosis with the physiologically based athlete’s heart or
ystemic hypertension—which may be difficult to resolve
n clinical grounds alone (2,10,62,63). However, clinical
nd molecular genotype-phenotype studies have triggered
he emergence of novel diagnostic criteria for HCM (1,2,
,10,20–22,24,64,65). As a consequence of these data, it is
ow evident that there is no true minimum LV wall
hickness diagnostic or pathognomonic for HCM (1,2,6,
0,18–24,28,29,64–76). Indeed, virtually any value for LV
all thickness, even when within the normal range (i.e.,
12 mm for adults), is consistent with the presence of a
CM-causing mutant gene.
EVELOPMENT OF LV HYPERTROPHY
ndividuals harboring a genetic defect for HCM do not
ecessarily express clinical markers of their disease, such as
V hypertrophy on echocardiogram, ECG abnormalities,
r disease-related symptoms, at all times during life
2,5,10,18–24,28,29,64–76). Indeed, there are probably
hree phases of life during which LV hypertrophy (identi-
able on a diagnostic echocardiogram) may appear for the
rst time in HCM, i.e., most commonly during adoles-
ence, but also earlier in preadolescent children or later in
dulthood.
However, these diverse clinical profiles, although dis-
ussed separately here, do not imply different etiologies,
enetic substrates, or nature of the LV hypertrophy, but
nly that LV wall thickening may appear or be evident at
ifferent ages in a given lifetime.
nset in adolescence. It is well established that LV
ypertrophy may be absent on echocardiogram in preado-
escent children affected by a mutant HCM gene (1–6,
0,18–24,28,29,65,68,69,73,75). However, marked LV re-
odeling with spontaneous de novo appearance or striking
volution of hypertrophy frequently occurs in association
ith accelerated body growth during the crucial five-year
eriod of the adolescent years (i.e., usually 13 to 17 years)
10,68,69,73,75). Morphologic expression is usually com-
lete when physical maturity is achieved at about 18 years of
ge. Within this period of time, dramatic increases in LV
all thickness are often evident, averaging about 100% in a
roup of patients (compared to an expected average increase
f only about 10%) (68). Therefore, it is common for young
ffected family members 13 years old to represent “silent” mene carriers during the pre-hypertrophic phase of HCM.
hese dramatic structural changes in adolescence appear
o be spontaneous events generally unrelated to the onset
f symptoms, disease progression, or cardiac events
10,68,69,73,75). Also, during this period of life, as LV
utflow tract geometry is altered with accelerated body
rowth, systolic anterior motion of the mitral valve causing
ynamic obstruction to LV outflow may develop for the first
ime (69).
Of note, abnormal 12-lead ECG patterns may be evident
ven before LV hypertrophy is detectable on echocardio-
ram, thereby potentially providing early clinical evidence
or mutant HCM genes (10,18,19,21,24,73,74,76). How-
ver, although a distinctly abnormal ECG can in some cases
e regarded as a surrogate clinical marker for the HCM
henotype, relatively minor ECG alterations often represent
onspecific or normal variants completely unrelated to
CM. Therefore, prudence should be exercised in assign-
ng genetically affected status to a HCM family member
ased solely on an altered ECG in the absence of LV
ypertrophy. Recent imaging studies with reduced load-
ependent tissue Doppler echocardiography provide evi-
ence that diastolic dysfunction may also precede the
ppearance of the HCM phenotype on echocardiogram
66,67). Nevertheless, in the absence of LV hypertrophy,
either the scalar ECG nor tissue Doppler echocardiogra-
hy would appear at present to convey sufficient sensitivity
r specificity to represent reliable diagnostic alternatives to
aboratory DNA testing.
arly onset. Left ventricular hypertrophy and clinical man-
festations of HCM may occasionally appear in symptom-
tic or asymptomatic infants or young children well before
dolescence, although the precise significance of this pre-
entation is incompletely understood in terms of the natural
istory of the disease and clinical management (77–80).
ndeed, young and often asymptomatic children of about 4
o 12 years of age with marked LV wall thickening relative
o body size are being recognized with greater frequency,
robably owing to the increasingly widespread practice of
linical and genetic family screening. At present, however,
pecific data are sparse (and follow-up relatively short) in
his subset of patients, and it is largely unresolved as to
hether or not (or how often) the appearance of hypertro-
hy particularly early in life represents a malignant genetic
ubstrate and an unfavorable clinical feature of the disease
ssociated with premature death or disease progression.
evertheless, when the HCM phenotype has been recog-
ized in infants and young children, it has often been
ssociated with severe heart failure and increased mortality
77–79,81).
ate onset. Recognition of age-related and incomplete
enetrance, with the initial appearance of LV hypertrophy
n HCM family members delayed well into adulthood, has
ltered the landscape of clinical pedigree screening in this
isease (1,2,6,10,18,19,21,22,24,28,71,82), and is the pri-
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Family Screening in HCM December 7, 2004:2125–32here have been numerous observations and reports sup-
orting morphologic conversions to the HCM phenotype
i.e., from normal wall thickness to LV hypertrophy) during
id-life and even beyond in relatives who could be regarded
s “silent” affected gene carriers of mutant genes
10,21,22,24,28,29,71) (Fig. 1). This aspect of the natural
igure 1. Late-onset left ventricular (LV) hypertrophy confined to the
pical region, documented by serial echocardiography in a 60-year-old
oman with familial hypertrophic cardiomyopathy (HCM) due to a
yosin-binding protein C mutation. The patient has remained free of
CM-related cardiac symptoms. (A) Apical four-chamber cross-sectional
iew obtained at 55 years of age as part of a cardiac evaluation unrelated to
CM, showing the absence of LV hypertrophy with apical endocardium
elineated by the broken line. (B) Similar echocardiographic cross-
ectional plane, five years later, showing marked segmental hypertrophy
onfined to the LV apex (asterisk and broken line), which has developed
ver that period of time. LA left atrium; MVmitral valve; RA right
trium; RV  right ventricle.istory of HCM was first described in cross-sectional fnvestigations of families genotyped to myosin-binding
rotein C mutations (28). In these studies, penetrance of the
CM phenotype was often incomplete in children and
oung adults, increased progressively with age, and was
irtually complete in the oldest patients.
Delayed development of LV hypertrophy well until into
dulthood in affected HCM relatives has been confirmed by
erial observations in individual patients studied with echo-
ardiography over substantial periods of time (21,28,71), as
ell as in the previously unreported patient depicted in
igure 1. These striking adult morphologic conversions
nvolve an increase in LV wall thickness averaging about
0% over 5 years and have been documented at 30 to 60
ears of age, largely unassociated with the development of
ignificant symptoms or outflow obstruction (21).
However, the precise frequency with which delayed-onset
V hypertrophy occurs in HCM is unknown owing to the
ractical difficulties in assembling such data and document-
ng these clinical occurrences. Indeed, adult morphologic
onversions could ultimately prove to be a relatively com-
on phenomenon, as suggested by the cross-sectional data
28), or are possibly rare as implied by the anecdotal clinical
xperience at present. This is largely because it has not been
ustomary clinical practice to perform repeated echocardio-
raphic examinations in adult family members or patients
uspected of having HCM (after obtaining a normal echo-
ardiogram over about 18 years of age), given the prior
ssumption that LV hypertrophy did not initially appear in
dulthood as well as the potentially long time intervals over
hich serial echocardiograms would be required to reliably
emonstrate (or exclude) LV wall thickness changes in adult
atients.
Delayed development of LV hypertrophy into adulthood
as most commonly been reported with mutations in
ardiac myosin-binding protein C (10,18,19,21–
4,28,35,67). However, other HCM-causing mutant genes
ave been associated with gene-positive, phenotype-
egative adult relatives (e.g., troponin-T and beta-myosin
eavy chain genes) (18,19,66,67), raising the distinct pos-
ibility that late-onset hypertrophy may occur with other
enetic substrates and be much more common than gener-
lly regarded at this early juncture. For example, not
ncommonly, HCM may be recognized for the first time
hen symptoms of heart failure appear at advanced ages of
60 years (2,5,10,41,57,82–87), although all such patients
robably have not harbored a dormant HCM phenotype
ince early in life. It should also be noted, in light of these
bservations and conjectures regarding increasing wall
hickness in adult HCM patients that it is also possible for
radual LV remodeling with regression of hypertrophy to
ccur during this period of life (74,88), particularly in
omen (88).
Based on the aforementioned novel echocardiographic-
olecular observations in HCM families, it is now an
navoidable conclusion that any HCM family member of
































































































2129JACC Vol. 44, No. 11, 2004 Maron et al.
December 7, 2004:2125–32 Family Screening in HCMtudies) can harbor the potential to develop LV hypertrophy
nd HCM at virtually any age. These considerations have
articular relevance for screening relatives in high-risk
amilies in which HCM-related sudden deaths may have
lready occurred. In such a clinical circumstance it is not
nly possible that a HCM family member will develop
henotypic expression of the disease for the first time as an
dult, but in the process also acquire risk factors for sudden
eath such as extreme magnitude of LV hypertrophy with
all thickness 30 mm (81,89). At present, conclusive data
inking adult patients with late-onset hypertrophy to any
articular prognosis are lacking and treatment algorithms
re unresolved, although the longitudinal follow-up of this
ewly recognized subset of patients is still brief. It should be
mphasized, however, that although sudden-death events
ccurring in HCM in the advance of obvious phenotypic
xpression have been reported (10,20,64,65,70,72), at this
ime they appear to be quite rare (2,10).
ECOMMENDATIONS FOR CLINICAL SCREENING
TRATEGIES IN HCM FAMILIES
n clinical practice, prospective screening of HCM family
embers to ascertain affected or unaffected genetic status
sually takes place without access to DNA analysis, and is
erformed primarily with two-dimensional echocardiogra-
hy and 12-lead ECG, as well as history and physical
xamination. Furthermore, most family screening is carried
ut by clinical cardiologists in the community; the relatively
mall number of HCM research centers do not possess the
esources necessary to routinely perform such clinical testing.
The traditional recommended strategy for screening rel-
tives in most HCM families calls for such evaluations on a
2- to 18-month basis, usually beginning at least by 12 years
f age (Table 1). If these studies do not show evidence of
V hypertrophy, with one or more segments of increased
all thickness, by the time full growth is achieved (at the
ge of about 18 to 21 years), it has been customary practice
able 1. Clinical Screening Strategies With Echocardiography
and 12-Lead ECG) for Detection of HCM in Families*
12 yrs old
Optional unless:
Malignant family history of premature HCM death or
other adverse complications
Competitive athlete in an intense training program
Onset of symptoms
Other clinical suspicion of early LV hypertrophy
2 to 18–21 yrs old†
Every 12–18 months
18–21 yrs old†
Probably about every 5 yrs, or more frequent intervals with a family
history of late-onset HCM and/or malignant clinical course
In the absence of laboratory-based genetic testing. †Age range takes into consider-
tion the acknowledged individual variability in achieving physical maturity.
ECG  electrocardiogram; HCM  hypertrophic cardiomyopathy; LV  left
entricular.o conclude that a HCM-mutant gene is probably absent and reassure family members accordingly that further echo-
ardiographic testing would therefore be unnecessary.
However, recognition of the aforementioned adult mor-
hologic conversions to the HCM phenotype has created a
ew proposed paradigm for screening families and genetic
ounseling in this disease, i.e., it is no longer possible to
outinely hold to the traditional tenet that a normal echo-
ardiogram (and ECG) obtained at maturity itself defines a
enetically unaffected relative. Consequently, we believe
hat it is now probably prudent to revise current practice
trategies and extend the time period into adulthood for the
linical-morphologic surveillance of those phenotype-
egative relatives judged to potentially harbor a mutant
CM gene (Table 1).
Specifically, at present, the recommended clinical model
or diagnosis of HCM would include serial two-
imensional echocardiographic (and ECG) examinations
erformed in adult family members without LV hypertro-
hy at about five-year intervals, past the end of adolescence
nd into mid-life, unless a clinical development intervenes
hat justifies a shorter interval (Table 1). Also, a family
istory suggestive of late-onset HCM (or malignant clinical
ourse) may justify repeated echocardiographic screening at
omewhat more frequent intervals during the adult years.
This recommendation, triggered by the recognized po-
ential for late-onset hypertrophy in family members, seems
easonable at present, and probably unavoidable in the
ontext of current clinical practice—at least until that future
ime when greater clarity has been achieved regarding this
henotypic evolution of HCM, including its frequency,
iming, and predisposing genetic substrates. Nevertheless,
e also recognize certain negative implications that could
esult from this strategy. By extending almost indefinitely
he period of morphologic (i.e., echocardiographic) surveil-
ance and clinical indecision regarding the diagnosis of
CM for family members we risk eliciting the psycholog-
cal perception and stigma of cardiac disease in young
ealthy individuals, many of whom are not even affected by
mutant gene. Indeed, at least 50% of adult relatives
xposed to serial echocardiography (as advocated here) will
e, by definition, free of any predisposition toward devel-
ping the disease or its consequences. Furthermore, this
roposed strategy potentially places a considerable burden
n echocardiographic resources considering the not incon-
equential number of HCM patients and families that could
e involved.
Our current approach for diffusing unnecessary anxiety in
dult phenotype-negative family members includes under-
coring the likelihood that they are unaffected relatives.
erforming additional serial echocardiograms may be a
rudent measure to more definitively resolve such diagnostic
ilemmas in individual family members and enable appro-
riate disease management. However, dependence on this
trategy requires considerable motivation by physicians and
t-risk individuals over potentially long periods of time. The
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Family Screening in HCM December 7, 2004:2125–32nnecessary anxiety (created by diagnostic uncertainty) may
e potentially alleviated by the recent development of rapid
aboratory-based genetic testing for HCM.
Indeed, a rapid genetic test for HCM is now available.
he Laboratory for Molecular Medicine (a clinical diagnos-
ic testing facility within the Harvard Partners Center for
enetics and Genomics [90]) currently analyzes by direct
NA sequencing the five most common HCM genes
beta-myosin heavy chain, myosin-binding protein C, car-
iac troponin T, cardiac troponin I, and alpha-tropomyosin)
or disease-causing mutations. The power of the test lies
ith its effectiveness and efficiency in determining the
equence of each of the genes involved and also in identi-
ying novel mutations (requiring only 7 cc of blood, and
ith genotyping results provided within one month). How-
ver, there remains the significant potential for false-
egative test results (in which a HCM diagnosis cannot be
uled out) owing to the possible presence of mutations in the
even known causal genes not yet part of the test panel, or
n other potential HCM genes not yet identified. As this
enetic test strategy evolves and comes into more wide-
pread clinical use, with its costs ultimately assumed by
nsurance companies, reliance on serial echocardiograms
nto adulthood for the diagnosis of family members will
iminish substantially.
Although open to individual clinical judgment, it has
een the common and generally accepted practice to avoid
outine echocardiographic studies in children younger than
bout 12 years of age owing to the infrequency with which
udden death or other disease complications occur in very
oung children, and because LV hypertrophy uncommonly
ppears this early in life. In addition, identification of the
CM phenotype will, per se, rarely trigger therapeutic
nterventions and management decisions in this age group.
urthermore, with repeated diagnostic testing in rapidly
rowing children, difficulties can arise with regard to accu-
ate interpretation of borderline LV wall thickness measure-
ents relative to body surface area for the diagnosis of
CM, which itself may create undo uncertainty and anxiety
n the part of patients and families.
However, not uncommonly, circumstances may arise that
ustify performing serial echocardiographic studies earlier in
articularly young family members. These may include
elatives in whom cardiac symptoms have already occurred,
hose involved in particularly intense competitive sports
rograms at this age (such as swimming, ice hockey, or
ennis), or suspected of having HCM by an echocardiogram
uring preadolescence (e.g., 10 to 12 years of age), as well as
embers of HCM families in which there have been prior
remature deaths and/or other malignant disease expression
2,91). In the latter patients, identification of early-onset
ypertrophy could possibly lead to recommendation for
ithdrawal from particularly vigorous and intense physical
ctivities and competitive sports (92), and in selected pa-
ients to a prophylactic intervention with an implantable
2ardioverter-defibrillator for primary prevention of sudden
eath (42,50).
eprint requests and correspondence: Dr. Barry J. Maron,
inneapolis Heart Institute Foundation, 920 E. 28th Street, Suite
0, Minneapolis, Minnesota 55407. E-mail: hcm.maron@
hif.org.
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